6 [9] M. Maiman, R. G. Fruchter, E. Serur, J. C. Remy, G. Feuer, and J. Boyce, “Human immunodeﬁciency virus infection and cervical neoplasia,” Gynecologic Oncology, vol. 38, no. 3, pp. 377–382, 1990. [10] D. J. Jamieson, A. Duerr, R. Burk et al., “Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection,” American Journal of Obstetrics and Gynecology, vol. 186, no. 1, pp. 21–27, 2002. [11] H. D. Strickler, R. D. Burk, M. Fazzari et al., “Natural history and possible reactivation of human papillomavirus in human immunodeﬁciency virus-positive women,” Journal of the National Cancer Institute, vol. 97, no. 8, pp. 577–586, 2005. [12] B. Ledergerber, A. Telenti, and M. Egger, “Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with potent antiretroviral therapy: Prospective cohort study,” British Med- ical Journal, vol. 318, no. 7201, pp. 23–24, 1999. [13] L. P. Jacobson, T. E. Yamashita, R. Detels et al., “Impact of potent antiretroviral therapy on the incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphomas among HIV-1— infected individuals,” Journal of Acquired Immune Deﬁciency Syndromes and Human Retrovirology, vol. 21, no. 4, pp. S34– S41, 1999. [14] J. M. Palefsky, “Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeﬁciency virus in the era of highly active antiretroviral therapy,” Current Opinion in Oncology, vol. 15, no. 5, pp. 382–388, 2003. [15] I. Heard, J. M. Palefsky, and M. D. Kazatchkine, “The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases,” Antiviral Therapy, vol. 9, no. 1, pp. 13–22, 2004. [16] C. S. Rabkin, R. J. Biggar, M. S. Baptiste, T. Abe, B. A. Kohler, and P. C. Nasca, “Cancer incidence trends in women at high risk of human immunodeﬁciency virus (HIV) infection,” International Journal of Cancer, vol. 55, no. 2, pp. 208–212, 1993. [17] X. W. Sun, L. Kuhn, T. V. Ellerbrock, M. A. Chiasson, T. J. Bush, and T. C. Wright, “Human papillomavirus infection in women infected with the human immunodeﬁciency virus,” New England Journal of Medicine, vol. 337, no. 19, pp. 1343– 1349, 1997. [18] S. Pecorelli, J. L. Benedet, W. T. Creasman et al., “FIGO staging of gynecologic cancer,” International Journal of Gynecology and Obstetrics, vol. 65, no. 3, pp. 243–249, 1999. [19] D. M. Parkin, S. L. Whelan, J. Ferlay, and H. Storm, Cancer Incidence in Five Continents, Vol. I to VIII, IARC CancerBase nu7, IARC, Lyon, France, 2005. [20] T. C. Wright Jr., L. S. Massad, C. J. Dunton, M. Spitzer, E. J. Wilkinson, and D. Solomon, “2006 consensus guidelines for the management of women with abnormal cervical can- cer screening tests,” American Journal of Obstetrics and Gyne- cology, vol. 197, no. 4, pp. 346–355, 2007. [21] G. P. Parham, V. V. Sahasrabuddhe, M. H. Mwanahamuntu et al., “Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, Zam- bia,” Gynecologic Oncology, vol. 103, no. 3, pp. 1017–1022, 2006. [22] V. V. Sahasrabuddhe, M. H. Mwanahamuntu, S. H. Vermund et al., “Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia,” British Journal of Cancer, vol. 96, no. 9, pp. 1480–1483, 2007. [23] N. Keita, G. M. Cliﬀord, M. Koulibaly et al., “HPV infection in women with and without cervical cancer in Conakry, Guinea,” British Journal of Cancer, vol. 101, no. 1, pp. 202–208, 2009. AIDS Research and Treatment [24] G. M. Cliﬀord, M. A. G. Gonc¸alves, and S. Franceschi, “Hu- man papillomavirus types among women infected with HIV: a meta-analysis,” AIDS, vol. 20, no. 18, pp. 2337–2344, 2006. [25] F. X. Bosch, A. Lorincz, N. Mun˜oz, C. J. L. M. Meijer, and K. V. Shah, “The causal relation between human papillomavirus and cervical cancer,” Journal of Clinical Pathology, vol. 55, no. 4, pp. 244–265, 2002. [26] J. Palefsky, “Biology of HPV in HIV infection,” Advances in Dental Research, vol. 19, no. 1, pp. 99–105, 2006. [27] S. E. Hawes, C. W. Critchlow, P. S. Sow et al., “Incident high- grade squamous intraepithelial lesions in senegalese women with and without human immunodeﬁciency virus type 1 (HIV-1) and HIV-2,” Journal of the National Cancer Institute, vol. 98, no. 2, pp. 100–109, 2006. [28] M. N. Didelot-Rousseau, N. Nagot, V. Costes-Martineau et al., “Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso,” British Journal of Cancer, vol. 95, no. 3, pp. 355–362, 2006. [29] C. Ng’andwe, J. J. Lowe, P. J. Richards, L. Hause, C. Wood, and P. C. Angeletti, “The distribution of sexually-transmitted Human Papillomaviruses in HIV positive and negative pa- tients in Zambia, Africa,” BMC Infectious Diseases, vol. 7, article no. 77, 2007. [30] S. E. Hawes, C. W. Critchlow, M. A. Faye Niang et al., “In- creased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeﬁciency virus type 1 and 2 infections,” Journal of Infectious Diseases, vol. 188, no. 4, pp. 555–563, 2003. [31] J. R. Moodley, M. Hoﬀman, H. Carrara et al., “HIV and pre- neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study,” BMC Cancer, vol. 6, article no. 135, 2006. [32] M. Temmerman, M. W. Tyndall, N. Kidula, P. Claeys, L. Muchiri, and W. Quint, “Risk factors for human papillo- mavirus and cervical precancerous lesions, and the role of con- current HIV-1 infection,” International Journal of Gynecology and Obstetrics, vol. 65, no. 2, pp. 171–181, 1999. [33] V. Leroy, J. Ladner, A. De Clercq et al., “Cervical dysplasia and HIV type 1 infection in African pregnant women: a cross sectional study, Kigali, Rwanda,” Sexually Transmitted Infections, vol. 75, no. 2, pp. 103–106, 1999. [34] R. Newton, J. Ziegler, V. Beral et al., “A case-control study of human immunodeﬁciency virus infection and cancer in adults and children residing in Kampala, Uganda,” International Jour- nal of Cancer, vol. 92, no. 5, pp. 622–627, 2001. [35] W. K. Sekirime and R. Gray, “HIV infection among Uganda women with cervical cancer: a retrospective study,” Gyneco- logic and Obstetric Investigation, vol. 63, no. 4, pp. 222–228, 2007. [36] R. Newton, A. Grulich, V. Beral et al., “Cancer and HIV infection in Rwanda,” Lancet, vol. 345, no. 8961, pp. 1378– 1379, 1995. [37] G. La Ruche, R. Ramon, I. Mensah-Ado et al., “Squamous intraepithelial lesions of the cervix, invasive cervical carci- noma, and immunosuppression induced by human immun- odeﬁciency virus in Africa,” Cancer, vol. 82, no. 12, pp. 2401– 2408, 1998. [38] F. Sitas, R. Pacella-Norman, H. Carrara et al., “The spectrum of HIV-1 related cancers in South Africa,” International Journal of Cancer, vol. 88, no. 3, pp. 489–492, 2000. [39] L. Stein, M. I. Urban, D. O’Connell et al., “The spectrum of human immunodeﬁciency virus-associated cancers in a South African black population: results from a case-control study,